Navigation Links
Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain,Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the,Knee

important in this typically elderly and vulnerable patient population and may potentially offer a safer treatment option in the management of chronic osteoarthritis pain. Importantly, the prolonged analgesic effect resulting from a single or stepped dose, localized administration of Adlea does not seem to be associated with the systemic side effects commonly associated with NSAIDs (gastrointestinal and renal toxicities, and impaired clotting), COX-2 inhibitors (cardiovascular risks and renal toxicity), or opioids (respiratory depression, nausea/vomiting, sedation, disorientation, physical dependence, and the risk of addiction).

About Osteoarthritis of the Knee

Osteoarthritis of the knee is a common, progressive disease in which the joint cartilage breaks down. This breakdown causes the bones to rub against each other resulting in stiffness, pain, and loss of movement in the joint. In advanced stages, the pain becomes intractable and disabling, limiting patients' mobility and activities. At least five million patients in the U.S. are suffering from moderate to severe osteoarthritis of the knee and are candidates for knee replacement or aggressive non-surgical interventions to address the debilitating effects of end-stage osteoarthritis of the knee.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has two drug candidates in development for multiple pain-related indications. A New Drug Application (NDA) has been filed for the most advanced product, Zingo(TM). The second product in the pipeline, Adlea (formerly 4975), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more info
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:9/17/2014)... EMERYVILLE, Calif. , Sept. 17, 2014 /PRNewswire/ ... newest data analytics solution that brings complete visibility ... minimize risks in an ever-evolving reimbursement landscape. Powered ... Integrity brings transparency to the critical point between ... operations impact revenue. The solution will improve revenue ...
(Date:9/17/2014)... -- Women everywhere know how frustrating a vaginal infection ... often also embarrassing and have a way of derailing ... http://ph-defense.com ) is a new, over-the-counter product designed to ... Odor, discharge, and discomfort or itch ... many cases, the cause of such problems can be ...
(Date:9/17/2014)... , Sept. 17, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... focused on licensing, developing and commercializing innovative biopharmaceutical ... of its public offering of 4,500,000 shares of its common ... $9.25 per share. Aratana has granted the underwriters ... additional 675,000 shares of its common stock. ...
Breaking Medicine Technology:MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3New Product from Vireo Systems: pH-D Feminine Health Support 2Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2
... Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today ... midazolam injection, USP, a general anesthetic.  Sagent expects ... latex-free vials, in 2011.  According to 2010 IMS ... approximated $52 million.   "Approval of ...
... Genous Stent shows favorable outcomes compared to bare metal stents ... to data published online in the journal Atherosclerosis ... primary endpoint, the composite of cardiac death, myocardial infarction (MI) ... 12.4% in patients treated with a Genous Stent, a 30% ...
Cached Medicine Technology:Sagent Pharmaceuticals Announces FDA Approval of Midazolam Injection, USP 2OrbusNeich's Genous™ Stent Shows Favorable Outcomes for Treatment of Coronary Artery Bifurcation Lesions Compared to Bare Metal Stents 2
(Date:9/17/2014)... damage to the ends of chromosomes could hold the key ... form of skin cancer according to new research from ... an important new genetic risk factor for melanoma. , It ... strongest indicators of those most at risk of developing melanoma. ... sun, as they burn more easily. , It now appears ...
(Date:9/17/2014)... North Central Surgical Center is proud to ... their top-notch services. The hospital was the recipient for ... surgery. , Hospital-wide, North Central was the recipient of ... this award for two years in a row (2013-2014). ... the nation for Patient Safety in 2014 and ranked ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Tidewater ... host recruit757’s scholarship workshop for football players and their ... Sept. 23. , Doors open at 6:30 p.m. for ... and speak to trainers and physical therapists. The workshop ... p.m. , The Newport News Tidewater Performance Center, which ...
(Date:9/17/2014)... Positive messages about the health benefits of quitting smoking ... study suggests. Although smokers who think quitting will ... harmful effects of smoking, researchers found smokers who believe ... "gain-framed," or positive, messages about how quitting will improve ... mix of both types of messages might get more ...
(Date:9/17/2014)... FRISCO, Texas (PRWEB) September 17, 2014 ... (EV-D68) outbreak that is hospitalizing scores of infants, children ... Louisiana, says Dr. Kirk Mahon, medical director of Legacy ... , “There have been no reported cases of EV-D68 ... Oklahoma and Louisiana, that could change,” he said. “Implementing ...
Breaking Medicine News(10 mins):Health News:Chromosome buffers hold key to better melanoma understanding 2Health News:North Central Surgical Center Receives Several Accolades 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 3Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:Legacy ER & Urgent Care Warns North Texans about Dangers of Enterovirus D68 2
... Medical Transcription announced today that Administrative Advantage has chosen ZyDoc,s ... , ... Hauppauge, New York (PRWEB) May ... that Administrative Advantage , a full-service medical transcription company ...
... Robert L. Williamson III, DDS of Raleigh Comprehensive and Cosmetic Dentistry ... to earn the certification for oral sedation dentistry. , ... ... Cosmetic Dentistry, Dr. Robert L. Williamson III and Associates, announced recently ...
... Access to Pixantrone through ProgramSEATTLE, May 5 Cell ... that pixantrone is now available on a named-patient basis ... healthcare professionals for the treatment of individual patients with ... standard therapies or is refractory to them. We know ...
... to Colleges and Universities , ... Baltimore, MD. (Vocus) ... has formally completed the acquisition of CMI Insurance, formerly a PSA ... Inc., the travel medical insurance entity within MEDEX Global ...
... Growth and Effective Expense ManagementContinued Progress on Debt ReductionBIRMINGHAM, ... HLS ) today reported its results of operations for ... showed consolidated net operating revenues of $475.1 million for ... for the first quarter of 2008, or an increase ...
... Every summer, valley businesses shed their business attire in exchange ... in the spirit of raising money for United Cerebral Palsy ... disabilities. This year, the theme is Camp Casual and ... 17th though businesses can choose to hold their event on ...
Cached Medicine News:Health News:Administrative Advantage Selects ZyDoc e-Transcription Platform for Clients 2Health News:Administrative Advantage Selects ZyDoc e-Transcription Platform for Clients 3Health News:Administrative Advantage Selects ZyDoc e-Transcription Platform for Clients 4Health News:Raleigh Comprehensive and Cosmetic Dentistry Earns Certification For Sedation Dentistry 2Health News:Raleigh Comprehensive and Cosmetic Dentistry Earns Certification For Sedation Dentistry 3Health News:Pixantrone Now Available in Europe on a Named-Patient Basis 2Health News:Pixantrone Now Available in Europe on a Named-Patient Basis 3Health News:Pixantrone Now Available in Europe on a Named-Patient Basis 4Health News:MEDEX Acquires CMI Insurance 2Health News:MEDEX Acquires CMI Insurance 3Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 2Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 3Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 4Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 5Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 6Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 7Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 8Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 9Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 10Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 11Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 12Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 13Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 14Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 15Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 16Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 17Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 18Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 19Health News:Valley Businesses Shedding Their Suits to Go Casual for a Cause 2
... The Vitros ECi brings true ... to immunodiagnostic testing. Highly sensitive assays ... oncology and bone metabolism testing are ... under development. The Vitros ECi can ...
... is a flexible system that ... environments small hospitals, backup ... satellite locations. The Vitros 250 ... can be automated or placed ...
... an effort to improve on the ... toxicology, abused drugs, and immunosuppressants tests, ... which incorporates random access capabilities. Although ... undergone several important changes in the ...
The IMx system is an automated analyzer designed to perform microparticle enzyme immunoassay (MEIA), fluorescence polarization immunoassay (FPIA) and ion capture technologies....
Medicine Products: